Michael D. Wyzga - Jun 3, 2022 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KA)

Role: Sr. VP & Chief Financial Officer
Signature: /s/ Marie Epstein, Attorney-in-Fact
Stock symbol: KA
Transactions as of: Jun 3, 2022
Transactions value $: -$3,449
Form type: 4
Date filed: 6/6/2022, 09:45 PM
Previous filing: Dec 3, 2021
Next filing: Dec 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KA	Common Stock	Sale	-$3.45K	-2.89K	-14.44%	$1.19	17.1K	Jun 3, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.14 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Content

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of shares of restricted stock granted to the Reporting Person. This sale is mandated by the Issuer, Yumanity Therapeutics, Inc., to satisfy tax withholding obligations by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.14 to $1.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Remarks:

Sr. VP & Chief Financial Officer